The Residual Risk Reduction initiative (R3i) is a worldwide, academic, multidisciplinary, non-profit, Swiss-law foundation established by international academic and clinical experts in recognition of the significant residual risk of macro-vascular events and micro-vascular complications, including risk from established risk factors (such as unhealthy lifestyles, dyslipidemia, high blood pressure, high blood sugar and obesity) as well as emerging risk factors, that persists in patients despite treatment with current, evidence-based medical care.
The R3i Foundation was formed to engage healthcare professionals in an innovative, global initiative focused on supporting academic research, professional and patient education and public health advocacy with the goal of significantly improving and extending the lives of millions of patients at risk for vascular events.
For more information about the R3i Foundation, please visit www.r3i.org
Company Details
- Employees
- 3
- Founded
- -
- Address
- St. Alban-Anlage 46, 4052 Basel,switzerland
- Industry
- E-Learning
- Website
- http://www.r3i.org
- Keywords
- Brooklyn.
- HQ
- 4052 Basel
R3i Foundation (Residual Risk Reduction) Questions
R3I Foundation (Residual Risk Reduction)'s website is http://www.r3i.org
R3I Foundation (Residual Risk Reduction)'s LinkedIn profile is https://ch.linkedin.com/company/r3ifoundation
R3I Foundation (Residual Risk Reduction) has
3 employees.
View email and phone details for 3
employees at R3I Foundation (Residual Risk Reduction).
R3I Foundation (Residual Risk Reduction)'s industry is
E-learning
R3I Foundation (Residual Risk Reduction)'s top competitors are
Kcmc B.v.,
Arteriosclerosis, Thrombosis, And Vascular Biology (Atvb),
Carbon Silicon Ventures,
Centre For Lifestyle Medicine And Behaviour: Climb,
Cell Reports Methods By Cell Press,
Fatima Hanif Foundation,
Artie Bars,
Nsfa,
Nuance Pharma,
Convergen Ai.
R3I Foundation (Residual Risk Reduction)'s categories are E-learning
R3I Foundation (Residual Risk Reduction)'s founding year is 2007
